Compare Compass Inc. Class A Common Stock (COMP) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Compass Inc. Class A Common Stock vs Crispr Therapeutics AG — how do they compare? Compass Inc. Class A Common Stock trades at $9.52 (market cap $7.05B), while Crispr Therapeutics AG trades at $50.61 (market cap $5.06B). The key difference: Compass Inc. Class A Common Stock is the larger of the two by market cap, and Compass Inc. Class A Common Stock is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Compass Inc. Class A Common Stock for 0 Days and Crispr Therapeutics AG for 77 Days on average.
| COMP | CRSP | |
|---|---|---|
Market Cap | $7.05B | $5.06B |
Volume | 15,310,192 | 1,678,371 |
Sector | Real Estate | Health |
52-Week High | $13.58 | $74.92 |
52-Week Low | $6.68 | $44.34 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $10.47B | $3.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Compass Inc. Class A Common Stock
Compass is a technology-enabled residential real estate company. Its platform provides agents with tools for customer relationships, marketing, client service, and transactions, alongside brokerage, title, escrow, and mortgage services.
Read more on COMP →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
